News
10 Health Care Stocks With Whale Alerts In Today's Session
9 Apr 24
Options
Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data
8 Apr 24
Analyst Color, Biotech, Large Cap, News, Health Care, Reiteration, Analyst Ratings, Trading Ideas, General
Reported Sunday, Alnylam Presents Results From The KARDIA-2 Phase 2 Study Of Zilebesiran Added To Standard Of Care Antihypertensives In Patients With Inadequately Controlled Hypertension
8 Apr 24
News
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
2 Apr 24
News, Trading Ideas
BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Maintains $234 Price Target
27 Mar 24
News, Price Target, Analyst Ratings
Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst Says Zilebesiran As Promising Opportunity In Addressing Global Hypertension Challenges
5 Mar 24
Analyst Color, Biotech, Equities, Large Cap, News, Health Care, Reiteration, Analyst Ratings, Trading Ideas, General
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $395 Price Target
5 Mar 24
News, Price Target, Reiteration, Analyst Ratings
10 Health Care Stocks Whale Activity In Today's Session
29 Feb 24
Options
Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today
28 Feb 24
News, Trading Ideas
Cantor Fitzgerald Maintains Neutral on Alnylam Pharmaceuticals, Lowers Price Target to $150
23 Feb 24
News, Price Target, Analyst Ratings
RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $235 Price Target
21 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $165 Price Target
20 Feb 24
News, Price Target, Reiteration, Analyst Ratings
RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $235 Price Target
20 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Goldman Sachs Downgrades Alnylam Pharmaceuticals: Here's What You Need To Know
16 Feb 24
Analyst Ratings
RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $235 Price Target
16 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $225
16 Feb 24
News, Price Target, Analyst Ratings
Why Is Alnylam Pharmaceuticals Stock Trading Lower On Thursday?
15 Feb 24
Biotech, Earnings, Large Cap, News, Guidance, Health Care, Movers, General
Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $200 Price Target
15 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Alnylam Earlier Announced Updates To The Statistical Analysis Plan For The HELIOS-B Phase 3 Study Of Vutrisiran; Will Include Updates To The Primary And Secondary Endpoint Structure; Topline Results Are Expected To Be Available In Late June Or Early July
15 Feb 24
Biotech, News, Guidance, General
Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $165 Price Target
15 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Press releases
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
7 Apr 24
Press Releases
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
20 Mar 24
Press Releases
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
13 Mar 24
Press Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
11 Mar 24
Press Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
7 Mar 24
News, Legal, Press Releases
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
5 Mar 24
Press Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
3 Mar 24
Press Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
28 Feb 24
News, Legal, Press Releases